Core Viewpoint - Establishment Labs Holdings Inc. reported a quarterly loss of $0.62 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.52, indicating a negative earnings surprise of -19.23% [1] Financial Performance - The company posted revenues of $44.12 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 1.85%, but down from $48.56 million in the same quarter last year [2] - Over the last four quarters, Establishment Labs has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Establishment Labs shares have increased approximately 32.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.7% [3] Future Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.41 on revenues of $46.42 million, and for the current fiscal year, it is -$1.80 on revenues of $179.45 million [7] Industry Context - The Medical Services industry, to which Establishment Labs belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, which may impact the stock's performance [8]

This company is expected to post quarterly loss of $0.52 per share in its upcoming report, which represents a year-over-year change of +20%. Revenues are expected to be $43.32 million, down 10.8% from the year-ago quarter. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Establishment Labs scored a strong price increase driven by investors' optimism, following its recent presentation at two investor conferences. In the f ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38593 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. OR British ...

Financial Data and Key Metrics - Total revenue for Q1 2024 was $37.2 million, a 20% decline year-over-year [75] - Gross profit for Q1 2024 was $24.4 million, or 65.6% of revenue, compared to $30.1 million or 64.7% in Q1 2023 [43] - Adjusted EBITDA improved to a loss of $3.7 million in Q1 2024, compared to a loss of $17.3 million in Q4 2023 and $4 million in Q1 2023 [50] - Operating expenses decreased to $33.2 million in Q1 2024, down $5 million year-over-year and $9.5 million sequentially [2] - SG&A expenses declined to $28.9 million in Q1 2024, down $2.8 million year-over-year and $8 million sequentially [49] - R&D expenses decreased to $4.3 million in Q1 2024, down $2.2 million year-over-year and $1.5 million sequentially [49] - Net loss from operations was $8.8 million in Q1 2024, compared to $8.2 million in Q1 2023 and $22.1 million in Q4 2023 [50] Business Line Data and Key Metrics - Direct sales accounted for 39% of implant sales in Q1 2024, with distributors making up the balance [75] - Mia Femtech has 55 clinics signed up, with 33 operating and 22 in the onboarding process [41] - Mia Femtech added centers in the Middle East and Latin America in Q1 2024, with clinics now in Riyadh, Jeddah, Dubai, Abu Dhabi, Beirut, and San Jose [41] - Flora tissue expander is gaining traction in the U.S. market, with adoption expected to grow throughout 2024 [46] - Motiva implants launched in China in Q1 2024, with strong early reception and aggressive marketing strategies in Tier 1 and Tier 2 cities [42] Market Data and Key Metrics - Europe, Middle East, and Africa accounted for 55% of global sales in Q1 2024, Asia Pacific 21%, and Latin America 23% [75] - Brazil, the largest market globally, accounted for 11% of total quarterly sales [75] - Demand in Latin America is lagging, with slower recovery expected compared to other regions [29] - China's market is recovering, with expectations to return to 2019 levels by 2025, potentially accelerated by stimulus packages [60] Company Strategy and Industry Competition - The company aims to achieve adjusted EBITDA positivity by the end of 2024 and cash flow positivity by the end of 2025, excluding U.S. investments [76] - The pending U.S. launch of Motiva implants is a key focus, with high confidence in approval in 2024 [74] - The company is building a strong commercial foundation for the U.S. launch, including hiring experienced leaders and expanding the sales force [79] - Mia Femtech is creating a new minimally invasive category in breast aesthetics, with significant market expansion potential [47] Management Commentary on Operating Environment and Future Outlook - The company sees steady recovery in markets, with improving demand in both direct and distributor channels [44] - Management expects sequential improvement in demand throughout 2024, with distributor orders returning to normalized levels [28] - The company is optimistic about achieving $1 million revenue per Mia clinic, with early clinics trending toward this goal [14] - The U.S. market for breast aesthetics is normalizing post-pandemic, with expectations for continued recovery [31] Other Important Information - The company received an investigational device exemption from the FDA for Motiva Implants and is undergoing a clinical trial for U.S. approval [24] - The 4-year data from the Motiva U.S. IDE study showed low complication rates, with only 2 cases of capsular contracture and 1 suspected rupture [45] - The company has $73 million in cash as of March 31, 2024, with access to an additional $50 million in debt facilities upon FDA approval and sales milestones [63] Q&A Session Question: Underlying assumptions and guidance [28] - The company expects sequential improvement in demand, with distributor orders returning to normalized levels and direct markets performing better [28] Question: Direct market trends and guidance assumptions [30] - Management feels confident about trending toward the upper end of the revenue guidance range for 2024, with similar sequential improvement expected in Q2 [30] Question: International distributor inventory levels [55] - Distributor inventory levels are normalizing, with demand improving globally, except in Latin America, where recovery is slower [29] Question: U.S. market health and Motiva launch [57] - The U.S. market is normalizing post-pandemic, with expectations for continued recovery, positioning the company well for the Motiva launch in late 2024 [31] Question: FDA inspection process and China stimulus impact [33] - The FDA inspection of the Costa Rica facility is scheduled within 30 days, with high confidence in U.S. approval in 2024 [7] - The China stimulus package is seen as a positive development, potentially accelerating market recovery [60] Question: Mia Femtech revenue contribution and clinic expansion [89] - The company has signed up 55 Mia clinics, with 33 operating and 37 under negotiation, aiming for 100 clinics by year-end [89] - Early clinics are trending toward $1 million revenue per clinic, with expectations for significant market expansion [14] Question: China market share and revenue expectations [67] - The company expects to match its market share in surrounding Asian countries (40%-70%) in China over the next few years [67] - Early results in China are tracking as expected, with strong reception for Motiva implants [42] Question: U.S. go-to-market strategy and sales force build-out [88] - The company is building a strong commercial foundation for the U.S. launch, including hiring experienced leaders and expanding the sales force [79] Question: International recon franchise traction [87] - Flora tissue expander is gaining traction in the U.S., with adoption expected to grow, while international recon traction is slower due to hospital tender processes [83] Question: Mia Femtech revenue breakout and clinic maturity [89] - The company is focused on qualitative growth for Mia Femtech, with revenue expected to become more material as the network of clinics expands [89]

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.48 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.77%. A quarter ago, it was expected that this company would post a loss of $0.95 per share when it actually produced a loss of $0.79, delivering a surprise of 16.84%.Over the last four quarters, the com ...

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 rdenhoy@establishmentlabs.com Establishment Labs Reports First Quarter 2024 Financial Results NEW YORK, NY, May 8, 2024 -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024. First Quarter Highlights and Outlook "We are o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38593 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British Virgin Islands 98 ...

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.84%. A quarter ago, it was expected that this company would post a loss of $0.72 per share when it actually produced a loss of $1.12, delivering a surprise of -55.56%.Over the last four quarters, the co ...

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided 2024 guidance. Fourth Quarter Highlights and Outlook 2024 revenue guidance of $174 million to $184 million, an increase of 5% to 11% over 2023. Guidance does not include revenue from M ...

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The terms on the two tranches already drawn under the facility, which total $175 million, are unchanged. The remaining two $25 million tranches are amended as follows: Tranche ...